Next Article in Journal
Cancer-Specifically Re-Spliced TSG101 mRNA Promotes Invasion and Metastasis of Nasopharyngeal Carcinoma
Previous Article in Journal
Lymphoproliferation Impairment and Oxidative Stress in Blood Cells from Early Parkinson’s Disease Patients
Previous Article in Special Issue
Neuropilins in the Context of Tumor Vasculature
Article Menu
Issue 3 (February-1) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2019, 20(3), 774;

Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers

Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, BC V6H 3Z6, Canada
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Received: 1 January 2019 / Revised: 5 February 2019 / Accepted: 8 February 2019 / Published: 12 February 2019
Full-Text   |   PDF [1967 KB, uploaded 12 February 2019]   |  
  |   Review Reports


The semaphorins represent a large family of signaling molecules with crucial roles in neuronal and cardiac development. While normal semaphorin function pertains largely to development, their involvement in malignancy is becoming increasingly evident. One member, Semaphorin 3C (SEMA3C), has been shown to drive a number of oncogenic programs, correlate inversely with cancer prognosis, and promote the progression of multiple different cancer types. This report surveys the body of knowledge surrounding SEMA3C as a therapeutic target in cancer. In particular, we summarize SEMA3C’s role as an autocrine andromedin in prostate cancer growth and survival and provide an overview of other cancer types that SEMA3C has been implicated in including pancreas, brain, breast, and stomach. We also propose molecular strategies that could potentially be deployed against SEMA3C as anticancer agents such as biologics, small molecules, monoclonal antibodies and antisense oligonucleotides. Finally, we discuss important considerations for the inhibition of SEMA3C as a cancer therapeutic agent. View Full-Text
Keywords: semaphorins; SEMA3C; inhibitors; plexins; neuropilins; cancer therapeutics semaphorins; SEMA3C; inhibitors; plexins; neuropilins; cancer therapeutics

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Hui, D.H.; Tam, K.J.; Jiao, I.Z.; Ong, C.J. Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers. Int. J. Mol. Sci. 2019, 20, 774.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top